




## ChemiScreen™ CALCIUM-OPTIMIZED STABLE CELL LINE HUMAN RECOMBINANT GPR91 SUCCINATE RECEPTOR

<b>CATALOG NUMBER:</b>	HTS241C	<b>QUANTITY:</b>	2 vials, 1 mL per vial
<b>LOT NUMBER:</b>	RI09010001	<b>CONCENTRATION:</b>	2 x 10 <sup>6</sup> cells/mL

**BACKGROUND:** GPR91 is a class A G-protein coupled receptor that binds selectively to succinate, an intermediate in the citric acid cycle, and couples to both the G<sub>i</sub>/G<sub>o</sub> and G<sub>q</sub> pathways. Renal proximal tubules are a major site of GPR91 expression, and succinate-mediated activation of renal GPR91 stimulates the release of renin to cause vasoconstriction and hypertension (He *et al.*, 2004). In addition, GPR91 in retinal neurons mediates retinal vascularization induced by succinate, which accumulates in response to hypoxia (Sapieha *et al.*, 2008). Dendritic cells also highly express GPR91, which mediates succinate-induced immune cell migration and activation *in vitro* and *in vivo* (Rubic *et al.*, 2008). Therefore, suppression of GPR91 is a potential strategy for treatment of vascular retinopathies, hypertension, and inflammation. Millipore's cloned human GPR91 -expressing cell line is made in the Chem-1 host, which supports high levels of recombinant GPR91 expression on the cell surface and contains high levels of the promiscuous G protein to couple the receptor to the calcium signaling pathway. Thus, the cell line is an ideal tool for screening for agonists and antagonists at GPR91.

**APPLICATIONS:** Calcium flux assay



**Figure 1.** Calcium flux in GPR91-expressing Chem-1 cell line. GPR91-expressing Chem-1 cells and Wild-Type Chem-1 cells (Millipore catalog # HTSCHEM-1) were loaded with a no-wash calcium assay kit, and calcium flux in response to succinate and  $\alpha$ -ketoglutarate was determined in triplicate on a Molecular Devices FLIPR<sup>TETRA</sup>™. In this experiment, average maximum signal was 3500 RLU. Z' was 0.685 with succinate at 2x EC50.



## ChemiScreen™ CALCIUM-OPTIMIZED STABLE CELL LINE HUMAN RECOMBINANT GPR91 SUCCINATE RECEPTOR

**Table I.** Comparison of EC50 values of GPR91-expressing Chem-1 cells with values described in the literature.

ligand	assay	potency ( $\mu\text{M}$ )	Reference
succinate	Calcium	EC50 = 143-200	Figure 1
succinate	Calcium	EC50 = 56	He <i>et al.</i> , 2004

HOST CELLS: Chem-1, a rat adherent cell line of hematopoietic origin expressing the promiscuous G-protein,  $G_{\alpha 15}$ .

TRANSFECTION: Proprietary plasmid pHS containing GPR91 cDNA (Accession Number: NM\_033050; see CODING SEQUENCE below). The stable clonal cell line was selected by resistance to geneticin, followed by limited dilution cloning. The cell line was tested and found to have equivalent EC50 and signal at 1, 3 and 6 weeks of continuous culture.

### PRESENTATION:

Cells are frozen at  $2 \times 10^6$  cells/mL in 90% fetal bovine serum/10% DMSO. Cell line tests negative for mycoplasma.

### STORAGE/HANDLING

:

1. Immediately upon receipt, thaw cells or place cells in liquid nitrogen.
2. Thaw cells rapidly by removing from liquid nitrogen and immediately immersing in a 37°C water bath. Immediately after ice has thawed, sterilize the exterior of the vial with 70% ethanol. Transfer contents of the vial to a T75 flask containing growth media. Place the flask in a humidified incubator at 37°C with 5%  $\text{CO}_2$ .
3. After 8-24 h, all live cells will be attached. Viability of the cells is expected to be 50-80%. At this time, replace media to remove residual DMSO, and return to incubator.
4. When cells are approximately 80% confluent, passage the cells as follows: Remove media and wash once with HBSS without  $\text{Ca}^{++}$  and  $\text{Mg}^{++}$  (10 mL/T75). Add 0.05% trypsin/0.2 g/L EDTA (1 mL/T75) and place in humidified incubator at 37°C with 5%  $\text{CO}_2$  until cells begin to round up and detach (5-10 minutes). Gently rap the side of the flask to dislodge the cells. Neutralize trypsin by addition of 4 mL Chem-1 Growth Media per 1 mL trypsin.
5. Cells are typically passaged 1:10 every 3-4 days. Passaging ratio may be varied according to requirements of the investigator.
6. Frozen stocks of cells should be prepared at the earliest passage possible after thawing, as follows: Count detached cells (prepared as in Step 4). Centrifuge cells at 200 x g for 5 min. Resuspend cells at  $5 \times 10^6$  cells/mL in Chem-1 Freezing Media (cell densities of  $2-10 \times 10^6$  are also acceptable if necessary). Dispense 1 mL aliquots into cryopreservation vials. Freeze the cells by a controlled rate process, such as in an isopropanol-jacketed container placed at  $-70^\circ\text{C}$  overnight. Store the vials in liquid nitrogen.



## ChemiScreen™ CALCIUM-OPTIMIZED STABLE CELL LINE HUMAN RECOMBINANT GPR91 SUCCINATE RECEPTOR

7. Use of cells immediately after thawing is feasible for some cell lines and is being further validated. Some cell lines may need to be passaged at least once after thawing prior to use in calcium flux assays. Cells should be resuspended in Chem-1 Plating Media for plating for calcium assay.

### MEDIA:

#### Chem-1 Growth Media:

DMEM with 4.5 g/L glucose and 4 mM glutamine (Millipore SLM-020-A)  
10% heat-inactivated FBS  
1x Nonessential amino acids (from 100x stock, Millipore TMS-001-C)  
10mM HEPES (from 1 M HEPES, Millipore TMS-003-C)  
1x Pen-Strep (from 100x stock, Millipore TMS-AB2-C)  
250µg/mL Genetecin/G-418

*Note: fetal bovine serum contains succinate in varying quantities. Improved succinate-induced calcium signal may be obtained in some cases by propagating and plating GPR91 cells in a serum-free media such as Ultraculture media (Lonza 12-725F)*

#### Chem-1 Plating Media:

DMEM with 4.5 g/L glucose and 4 mM glutamine  
10% heat-inactivated FBS  
1x NEAA  
10mM HEPES  
1x Pen-Strep

#### Chem-1 Freezing Media:

90% heat-inactivated FBS  
10% DMSO (cell culture grade)

### EXAMPLE ASSAY CONDITIONS:

1. Cells propagated for screening should be maintained and seeded at less than 90% confluency. Trypsinize cells as above and seed cells in 96-well black-walled, clear bottom plate at 50,000 cells/well in Chem-1 Plating Media. Keep the plate at room temperature for 1 h to allow even cell distribution in the plate, then transfer plate to a humidified incubator at 37°C with 5% CO<sub>2</sub>.
2. Chem-1 derived cell lines have been successfully assayed using multiple commercially-available calcium dye kits following the manufacturer's protocols. The protocol described below is a suggested protocol that can be generally applied to most calcium dyes kits.
3. Remove media
4. Wash cells with buffered salt solution
5. Add 100 µL/well calcium dye-loading solution.
6. Incubate the plate for 30 minutes in a humidified incubator at 37°C with 5% CO<sub>2</sub>.
7. Incubate the plate for an additional 60 min at 25°C with 5% CO<sub>2</sub>.
8. Set-up FLIPR to dispense 50µL/well 3X ligand to appropriate wells in the assay plate. Set excitation wavelength at 470-495 nm (FLIPR<sup>TETRA</sup>) or 485 nm (FLIPR1, FLIPR2, FLIPR3) and emission wavelength at 515-565 nm (FLIPR<sup>TETRA</sup>) or emission filter for Ca<sup>2+</sup> dyes (FLIPR1, FLIPR2, FLIPR3). Set pipet tip height at 95 uL and dispense rate



## ChemiScreen™ CALCIUM-OPTIMIZED STABLE CELL LINE HUMAN RECOMBINANT GPR91 SUCCINATE RECEPTOR

to 25  $\mu$ L/sec. Set up plate layout and tip layout for each individual experiment. Set time course for 180 seconds, with ligand addition at 10 seconds.

9. Ligands are prepared in a white nonbinding surface 96-well plate (Corning 3605).
10. After the run is complete, negative control correction is applied and data analyzed utilizing the maximum statistic.

### REFERENCES:

He W *et al.* (2004) Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. *Nature*. 429: 188-193.

Rubic T *et al.* (2008) Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. *Nat. Immunol.* 9: 1261-1269.

Sapieha P *et al.* (2008) The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. *Nat. Med.* 14: 1067-1076.

### CODING SEQUENCE:

```
ATG CTG GGG ATC ATG GCA TGG AAT GCA ACT TGC AAA AAC TGG CTG GCA GCA GAG GCT GCC CTG GAA AAG
M L G I M A W N A T C K A N W L A A E A A L E K
TAC TAC CTT TCC ATT TTT TAT GGG ATT GAG TTC GTT GTG GGA GTC CTT GGA AAT ACC ATT GTT GTT TAC
Y Y L S I F Y G I E F V V G V L G N T I V V Y
GGC TAC ATC TTC TCT CTG AAG AAC TGG AAC AGC AGT AAT ATT TAT CTC TTT AAC CTC TCT GTC TCT GAC
G Y I F S L K N W N S S N I Y L F N L S V S D
TTA GCT TTT CTG TGC ACC CTC CCC ATG CTG ATA AGG AGT TAT GCC AAT GGA AAC TGG ATA TAT GGA GAC
L A F L C T L P M L I R S Y A N G N W I Y G D
GTG CTC TGC ATA AGC AAC CGA TAT GTG CTT CAT GCC AAC CTC TAT ACC AGC ATT CTC TTT CTC ACT TTT
V L C I S N R Y V L H A N L Y T S I L F L T F
ATC AGC ATA GAT CGA TAC TTG ATA ATT AAG TAT CCT TTC CGA GAA CAC CTT CTG CAA AAG AAA GAG TTT
I S I D R Y L I I K Y P F R E H L L Q K K E F
GCT ATT TTA ATC TCC TTG GCC ATT TGG GTT TTA GTA ACC TTA GAG TTA CTA CCC ATA CTT CCC CTT ATA
A I L I S L A I W V L V T L E L L P I L P L I
AAT CCT GTT ATA ACT GAC AAT GGC ACC ACC TGT AAT GAT TTT GCA AGT TCT GGA GAC CCC AAC TAC AAC
N P V I T D N G T T C N D F A S S G D P N Y N
CTC ATT TAC AGC ATG TGT CTA ACA CTG TTG GGG TTC CTT ATT CCT CTT TTT GTG ATG TGT TTC TTT TAT
L I Y S M C L T L T L G F L I P L F V M C F F Y
TAC AAG ATT GCT CTC TTC CTA AAG CAG AGG AAT AGG CAG GTT GCT ACT GCT CTG CCC CTT GAA AAG CCT
Y K I A L F L K Q R N R Q V A T A L P L E K P
CTC AAC TTG GTC ATC ATG GCA GTG GTA ATC TTC TCT GTG CTT TTT ACA CCC TAT CAC GTC ATG CGG AAT
L N L V I M A V V I F S V L F T P Y H V M R N
GTG AGG ATC GCT TCA CGC CTG GGG AGT TGG AAG CAG TAT CAG TGC ACT CAG GTC GTC ATC AAC TCC TTT
V R I A S R L G S W K Q Y Q C T Q V V I N S F
TAC ATT GTG ACA CGG CCT TTG GCC TTT CTG AAC AGT GTC ATC AAC CCT GTC TTC TAT TTT CTT TTG GGA
Y I V T R P L A F L N S V I N P V F Y F L L G
GAT CAC TTC AGG GAC ATG CTG ATG AAT CAA CTG AGA CAC AAC TTC AAA TCC CTT ACA TCC TTT AGC AGA
D H F R D M L M N Q L R H N F K S L T S F S R
TGG GCT CAT GAA CTC CTA CTT TCA TTC AGA GAA AAG TGA
W A H E L L L S F R E K Stp
```

*For research use only; not for use as a diagnostic.*



## ChemiScreen™ CALCIUM-OPTIMIZED STABLE CELL LINE HUMAN RECOMBINANT GPR91 SUCCINATE RECEPTOR

### GMO

**This product contains genetically modified organisms.**

**Este producto contiene organismos genéticamente modificados.**

**Questo prodotto contiene degli organismi geneticamente modificati.**

**Dieses Produkt enthält genetisch modifizierte Organismen.**

**Ce produit contient organismes génétiquement des modifiés.**

**Dit product bevat genetisch gewijzigde organismen.**

**Tämä tuote sisältää geneettisesti muutettuja organismeja.**

**Denna produkt innehåller genetiskt ändrade organismer.**

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

©2009: Millipore Corporation. All rights reserved. No part of these works may be reproduced in any form without permission in writing.



## ChemiScreen™ CALCIUM-OPTIMIZED STABLE CELL LINE HUMAN RECOMBINANT GPR91 SUCCINATE RECEPTOR

### User Agreement (Label License) for ChemiScreen™ CALCIUM-OPTIMIZED STABLE CELL LINE HUMAN RECOMBINANT GPR91 SUCCINATE RECEPTOR

#### Product No. HTS241C

BY USING THE THIS PRODUCT LICENSED TO YOU (“LICENSEE”) HEREUNDER, YOU ARE HEREBY REPRESENTING THAT YOU HAVE THE RIGHT AND AUTHORITY TO LEGALLY BIND YOURSELF OR YOUR COMPANY, AS APPLICABLE, AND ARE CONSENTING TO BE LEGALLY BOUND BY ALL OF THE TERMS OF THIS USER AGREEMENT (“AGREEMENT”). IF YOU DO NOT AGREE TO ALL THESE TERMS, DO NOT USE THE PRODUCT, AND IMMEDIATELY RETURN SUCH PRODUCTS TO THE APPLICABLE SELLER FOR A REFUND. This is a legal agreement between Licensee and Millipore governing use of the ChemiScreen™ Calcium-Optimized Stable GPCR cell line products and/or any accompanying operating/use protocols (the “Product(s)”) provided to Licensee.

LICENSEE shall obtain no ownership interest in the Product or use/culture protocols accompanying the Product other than through the perpetual limited license granted herein. If the Product is licensed through an authorized Millipore distributor, Licensee shall be obligated to disclose its identity to Millipore to insure compliance with this User Agreement.

**Limited License and Restrictions.** Pursuant to the terms and conditions of this Agreement, Millipore conveys to Licensee the non-exclusive and non-transferable right to use the Licensed Product only for Research Purposes conducted by Licensee (whether Licensee is an academic user or a for-profit entity). “Research Purposes” means any biological research and development application or use, including without limitation, developing, demonstrating or validating biological assays, life sciences and/or pharmaceutical research. “Research Purposes” excludes applications outside biology (including but not limited to consumer electronics or materials sciences), and specifically excludes the following applications of whatever kind or nature: Clinical Diagnostics (any use of a product or service for clinical diagnosis where data from an individual’s sample is given to such individual or used for the purpose of diagnosis or treatment of a medical condition in such individual, where that result may be used in the treatment of such individual), therapeutics, clinical imaging, environmental testing and cosmetics. Licensee cannot sell or otherwise transfer (a) this Product or (b) materials made using this Product to a third party. Licensee may transfer information or materials made through use of this Product to a scientific collaborator, provided that such transfer is not for the commercial purposes, and that such collaborator agrees in writing: (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for Research Purposes and not for commercial purposes. Commercial purposes means any activity by a user of the Product for consideration that may include, but is not limited to: (1) operating a service business that uses the Products to develop information or data which is resold for research and development applications; (2) use of the Product in manufacturing; (3) use of the Product for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the Product, whether or not such Product is resold for use in research. Licensee expressly represents and warrants to Millipore that Licensee will properly test and use any Product purchased from Millipore or its affiliated companies in accordance with the practices of a reasonable person who is an expert in the field and in strict compliance with all applicable laws and regulations, now and hereinafter enacted. Licensee agrees to comply with instructions, if any, furnished by Millipore relating to the use of the Product and to not misuse the Product in any manner. Licensee shall not reverse engineer, disassemble or modify the Product or create any derivative works of the written materials accompanying the Product, including but not limited to any material data sheets or similar materials with respect to the Products’ specifications. Licensee acknowledges that Millipore or its affiliated companies retains ownership of all patents, copyrights, trademarks, trade secrets and other proprietary rights relating to or residing in the Product or any portion thereof.

**Licensee’s Representations.** Licensee agrees, and further represents and warrants: (i) that it shall use all Products solely in accordance with this Agreement, and that any such use of Products will not violate any applicable law, regulation, judicial order, or injunction; and (ii) that it is not prohibited from receiving the Products under U.S. export laws, that it is not a national of a country subject to U.S. trade sanctions, that it will not use the Products in a location that is the subject of U.S. trade sanctions that would cover the Products, and that, to its knowledge, it is not on the U.S. Department of Commerce’s table of deny orders or is otherwise prohibited from obtaining goods of this sort from the United States.

**No Warranties.** TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, MILLIPORE AND ITS AFFILIATED COMPANIES DO NOT WARRANT THAT THE USE OF THE PRODUCTS DELIVERED HEREUNDER WILL NOT INFRINGE THE CLAIMS OF ANY UNITED STATES OR OTHER PATENTS COVERING THE PRODUCT THEMSELVES OR THE USE THEREOF IN COMBINATION WITH OTHER PRODUCTS OR IN THE OPERATION OF ANY PROCESS. IN ADDITION, THE PRODUCTS ARE PROVIDED “AS IS,” WITHOUT WARRANTY OF ANY KIND, AND MILLIPORE MAKES NO WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE PRODUCTS OR



## ChemiScreen™ CALCIUM-OPTIMIZED STABLE CELL LINE HUMAN RECOMBINANT GPR91 SUCCINATE RECEPTOR

THE USE THEREOF. MILLIPORE AND ITS AGENTS HEREBY SPECIFICALLY DISCLAIM THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ACCURACY, TITLE AND THE IMPLIED CONDITION OF SATISFACTORY QUALITY. LICENSEE ASSUMES ALL RESPONSIBILITIES FOR SELECTION OF THE PRODUCT TO ACHIEVE ITS INTENDED RESULTS, AND FOR THE USE OF THE PRODUCT.

**Term and Termination.** This Agreement commences upon Licensee's use of the Products, and shall remain in effect in perpetuity unless terminated sooner as set forth hereunder. Millipore may terminate this Agreement immediately if Licensee breaches any provision herein. Upon any such termination, all rights granted to Licensee hereunder will immediately terminate, and Licensee shall immediately cease using the Product and, at Millipore's option, return or destroy all Products (certifying such destruction to Millipore in writing).

**Assignment.** Licensee shall not sublicense, assign (by operation of law or otherwise) or otherwise transfer this Agreement or any of the rights or licenses granted under this Agreement without the prior written consent of Millipore. Any attempted assignment, sublicense or transfer by Licensee without such consent shall be null and void.

**Miscellaneous.** This Agreement constitutes the entire agreement between Millipore and Licensee, and no modification or amendment shall be effective unless signed in writing by authorized representatives of both parties. Millipore's failure to strictly enforce any term or condition of this order or to exercise any right, power, or privilege arising hereunder shall not constitute a waiver of Millipore's right to strictly enforce such terms or conditions or exercise such right, power, or privilege thereafter. All rights and remedies under this order are cumulative and are in addition to any other rights and remedies Millipore may have at law or in equity. Any waiver or default by Licensee hereunder shall be in writing and shall not operate as a waiver of any other default or of the same default thereafter. If any provision of this Agreement shall be held invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions, rights, powers, and privileges shall not be affected or impaired thereby. The paragraph headings herein are for convenience only and form no part of the terms and conditions and shall not affect the interpretation of the terms and conditions. This Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto, and their respective heirs, personal representatives, corporate representatives, agents, successors, and assigns. THIS AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF CALIFORNIA, WITHOUT REFERENCE TO CONFLICT OF LAWS PRINCIPLES. ALL DISPUTES ARISING OUT OF OR RELATED TO THIS AGREEMENT WILL BE SUBJECT TO THE EXCLUSIVE JURISDICTION AND VENUE OF THE CALIFORNIA STATE COURTS OF SAN DIEGO COUNTY, CALIFORNIA (OR, IF THERE IS EXCLUSIVE FEDERAL JURISDICTION, A UNITED STATES SOUTHERN DISTRICT COURT OF CALIFORNIA), AND THE PARTIES CONSENT TO THE PERSONAL AND EXCLUSIVE JURISDICTION OF THESE COURTS.